Download PDF
Int J Sports Med 2000; 21(6): 424-428
DOI: 10.1055/s-2000-3838
Physiology and Biochemistry
Georg Thieme Verlag Stuttgart · New York

Montelukast does not Affect Exercise Performance at Subfreezing Temperature in Highly Trained Non-Asthmatic Endurance Athletes

M. Sue-Chu1 ,  M. Sandsund2 ,  B. Holand2 ,  L. Bjermer1
  • 1 Department of Lung Medicine, University Hospital, Norwegian University of Science and Technology
  • 2 Division of Extreme Work Environment, SINTEF Unimed, Trondheim, Norway
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at - 15 °C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [V˙O2 max] > 70 ml × kg-1 × min-1). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50 %, runs of 10 min at 90 % and 5 min at 80 % V˙O2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80 % V˙O2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes.

Key words:

Montelukast, leukotriene receptor antagonists, physical performance, endurance athletes.

References

  • 1 Aquilina A T. Comparison of airway reactivity induced by histamine, methacholine, and isocapine hyperventilation in normal and asthmatic subjects.  Thorax. 1983;  38 766-770
    PubMedGoogle Scholar
  • 2 Beck K C, Offord K P, Scanlon P D. Bronchoconstriction occurring during exercise in asthmatic subjects.  Am J Respir Crit Care Med. 1994;  149 352-357
    PubMedGoogle Scholar
  • 3 Burke J A, Levi R, Guo Z-g, Corey E J. Leukotrienes C4, D4 and E4: Effects on human and guinea-pig cardiac preparations in vitro.  J Pharm Exp Ther. 1982;  221 235-241
    PubMedGoogle Scholar
  • 4 Cheng H, Leff J A, Amin R, Gertz B J, De Smet M, Noonan N, Rogers N, Malbecq J D, Meisner W, Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.  Pharm Res. 1996;  13 445-448
    CrossrefPubMedGoogle Scholar
  • 5 Dahlén S E. Leukotriene receptors and their antagonists. In: Holgate S, Dahlén S-E (eds) SRS-A to Leukotrines. The Dawning of a New Treatment. London; Blackwell Science Ltd. 1997: 155-166
    Google Scholar
  • 6 De Lepeleire I, Reiss T F, Rochette F, Botto A, Zhang J, Kundu S, Decramer M. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.  Clin Pharmacol Ther. 1997;  61 83-92
    CrossrefPubMedGoogle Scholar
  • 7 Dempsey J A, Hanson P, Henderson K S. Exercise-induced arterial hypoxemia in healthy human subjects at sea level.  J Physiol. 1984;  355 161-171
    CrossrefPubMedGoogle Scholar
  • 8 Kaelin M, Brandli O. Exertional asthma in Swiss top-ranking athletes.  Schweiz Med Wochenschr. 1993;  123 174-182
    PubMedGoogle Scholar
  • 9 Kikawa Y, Hosoi S, Inoue Y, Saito M, Nakai A, Shigematsu Y, Hirao Y, Sudo T. Exercise-induced urinary excretion of leukotriene E4 in children with atopic asthma.  Pediatr Res. 1991;  29 455-459
    PubMedGoogle Scholar
  • 10 Larsson K, Ohlsen P, Larsson L, Malmberg P, Rydstrom P O, Ulriksen H. High prevalence in asthma in cross country skiiers.  Br Med J. 1993;  307 1326-1329
    PubMedGoogle Scholar
  • 11 Leff J A, Busse W W, Pearlman D, Bronsky D, Kemp E A, Hendeles J, Dockhorn L, Kundu R, Zhang S, Seidenberg J, Reiss T F. Montelukast, for the treatment of mild asthma and exercise-induced bronchoconstriction.  New Engl J Med. 1998;  339 147-152
    CrossrefPubMedGoogle Scholar
  • 12 Messina E J, Rodenburg J, Kaley G. Microcirculatory effects of leukotrienes, LTC4 and LTD4, in rat cremaster muscle.  Microcirc Endothelium Lymphatics. 1988;  4 355-376
    PubMedGoogle Scholar
  • 13 Ramage L, Lipworth B J, Ingram C G, Cree I A, Dhillon D P. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol.  Respir Med. 1994;  88 363-368
    CrossrefPubMedGoogle Scholar
  • 14 Reiss T F, Hill J B, Harman E, Tanaka W K, Bronsky E, Guerreiro D, Hendeles L. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchoconstriction by montelukast, a cysteinyl leukotriene antagonist.  Thorax. 1997;  52 1030-1035
    PubMedGoogle Scholar
  • 15 Reiss T F, Sorkness C A, Stricker W, Botto A, Busse W W, Kundu S, Zhang J. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids.  Thorax. 1997;  52 45-48
    PubMedGoogle Scholar
  • 16 Robuschi M, Riva E, Fuccella L M, Vida E, Barnabe R, Rossi M, Gambaro G, Spagnotto S, Bianco S. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK & F 104353). A double-blind study versus disodium cromoglycate and placebo.  Am Rev Respir Dis. 1992;  145 1285-1288
    PubMedGoogle Scholar
  • 17 Sandsund M, Sue-Chu M, Helgerud J, Reinertsen R E, Bjermer L. Effects of cold exposure (- 15 °C) and Salbutamol treatment of physical performance in elite non-asthmatic cross-country skiers.  Eur J Appl Physiol. 1998;  77 297-304
    CrossrefPubMedGoogle Scholar
  • 18 Smith L J, Geller S, Ebright L, Glass M, Thyrum P T. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI204,219.  Am Rev Respir Dis. 1990;  141 988-992
    PubMedGoogle Scholar
  • 19 Sorkness C A. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma.  Pharmacotherapy. 1997;  17 50 S-54 S
    PubMedGoogle Scholar
  • 20 Sue-Chu M, Larsson L, Bjermer L. Prevalence of asthma in young cross-country skiers in central Scandinavia: differences between Norway and Sweden.  Respir Med. 1996;  90 99-105
    PubMedGoogle Scholar
  • 21 Sue-Chu M, Sandsund M, Helgerud J, Reinertsen R E, Bjermer L. Salmeterol does not affect physical performance in highly-trained nonasthmatic cross country skiers.  Scand J Med Sci Sports. 1999;  9 48-52
    PubMedGoogle Scholar
  • 22 Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.  Am Intern Med. 1997;  126 177-183
    PubMedGoogle Scholar
  • 23 Weiler J M, Metzger W J, Donnelly A L, Crowley E T, Sharath M D. Prevalence of bronchial hyperresponsiveness in highly trained athletes.  Chest. 1986;  90 23-28
    PubMedGoogle Scholar
  • 24 Wensing G, Heinig R, Priesnitz M, Kuhlmann J. Effect of BAY x7195, an oral receptor antagonist of cysteinyl leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers.  Eur J Clin Pharmacol. 1994;  47 227-230
    PubMedGoogle Scholar
  • 25 Williams J H, Powers S K, Stuart M K. Hemoglobin desaturation in highly trained athletes during heavy exercise.  Med Sci Sports Exerc. 1986;  18 168-173
    PubMedGoogle Scholar

Malcolm Sue-Chu,MB ChB, FRCA 

Department of Lung Medicine University Hospital

N-7006 Trondheim Norway

Phone: Phone:+ 47 (73) 868596

Fax: Fax:+ 47 (73) 867424

Email: E-mail:malcolm.suechu@sensewave.com

      >